Bioharvest Sciences Inc.

BHST Nasdaq SEC CIK 1723464
Follow Bioharvest Sciences Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · US GAAP
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
  • Revenue
  • Net income
−$20M$0$20M$40MFY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$34.5M−$11.1M
FY24$25.2M−$12.9M
FY23$12.7M−$12.6M
FY22--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−100%−50%0%50%100%FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2559.3%−16.2%−32.3%
FY2455.4%−27.7%−51.3%
FY2344.5%−78.6%−99.1%
FY22---
Free cash flowOperating cash flow minus capital expenditure
−$10M−$7.5M−$5M−$2.5M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$9.6M
FY24−$9.5M
FY23−$10M
FY22-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Bioharvest Sciences
  • Healthcare median
−100%−75%−50%−25%0%FY22FY23FY24FY25
Show the numbers
YearBioharvest SciencesHealthcare median
FY25−32.3%−30.6%
FY24−51.3%−47%
FY23−99.1%−58%
FY22-−80.4%